April 19, 2017 — REMyDI (Rapid Estimation of Myelin for Diagnostic Imaging), first introduced by SyntheticMR AB at the 2016 Radiological Society of North America (RSNA) annual meeting, is now CE-marked for clinical use in Europe.
Easy quantification of myelin allows clinicians to follow myelination in the developing brain and monitor myelin degeneration in patients with demyelinating and neurodegenerative disorders. REMyDI is a feature of the SyMRI post-processing software from SyntheticMR.
Measuring myelin volume with conventional magnetic resonance imaging (MRI) is challenging. With the REMyDI feature in SyMRI, clinicians can now get an automatic volume measurement of myelin from a single 5-6 minute quantitative MRI scan. The automatic post-processing is completed in less than 10 seconds.
The new feature is now available in the SyMRI Neuro REMyDI package.
SyMRI is compatible with MR scanners from leading vendors. SyMRI is a CE-marked product and is U.S. Food and Drug Administration (FDA) 510(k) pending.
For more information: www.syntheticmr.com
April 18, 2025 
